|
|
 |
|
Viewing report
|
|
|
|
The Pharmaceutical Market: Peru
Espicom Business Intelligence Ltd, Aug 2009, Pages: 100
The pharmaceutical market is valued at US$1.1 billion at retail prices in 2009. According to the Ministry of Health (MINSA), the pharmacy sector represents 72% of the market at manufacturers. prices, and the hospital sector 28%. Historically, growth in pharmaceutical expenditure has been positive but unstable. Between 2009 and 2014, annual growth in pharmaceutical expenditure at retail prices is expected to be 5%.
USA - Peru Trade Promotion Agreement Effective from February 2009. The agreement should result in further intellectual property compliance by the pharmaceutical industry, a more competitive market and more widespread generics use by the government.
Counterfeit medicine bill passed. In May 2008, the Congressional Health Commission passed a bill to crack down on counterfeit medicines, introducing a maximum 10 year prison sentence for those that sell, store or produce fake medicine. The penal code was amended, making sentencing tougher for counterfeiters, smugglers and dealers. Around 30% of medicine sold in Peru is adulterated.
Emerging urban population demanding better healthcare. Per capita wealth has risen, especially around Lima, leading to a sizeable urban population which demands improved healthcare and has the ability to pay for it.
Domestic producers produce branded and unbranded generics. Imports of original drugs are generally consumed by the pharmacy sector, whilst locally produced branded and unbranded generics are consumed by the pharmacy and hospital sectors. Leading domestic producers include Farmindustria, Infarmasa Corporation (Magma and Sanitas), Medifarma and Medco Corporation (Cofana and Marfan).
Universal Health Insurance Law approved and reverse auctions continue. Around 42% of Peruvians are poor and, of these, only 23% can buy medicines. A Universal Health Insurance Law was approved in December 2008, to help the poor access healthcare. The first reverse auction for medicine, worth US$46 million, was held in December 2006, saving around US$12 million. Several further auctions have been held since.
High inflation and a revised GDP forecast. Peru has high inflation and a rapid reduction is not foreseen in the near future. The National Statistics Institute found the 2008 domestic inflation level to be 7.3%. Purchasing power has been reduced on a large scale, particularly amongst the poorest regions of the country and the capital, Lima, has high levels of poverty. Short term GDP forecasts have been revised downwards to reflect current global economic conditions. For 2009 the government is activating a US$5,800 million ''Anticrisis Plan'' to sustain economic growth in the global downturn.
Customers who bought this item also bought
Peru Pharmaceuticals and Healthcare Report Q4 2009
Peru Pharmaceuticals and Healthcare Report Q1 2009
Peru Pharmaceuticals and Healthcare Report Q3 2008
Peru Pharmaceuticals and Healthcare Report Q2 2009
Peru Pharmaceuticals and Healthcare Report Q1 2008
The Medical Device Market: Peru
Peru Retail Report Q4 2009
The Pharmaceutical Market: Portugal
Indian Generics, 2008-2012: The Growing Threat to Westernised Markets
Company Study of Huadong Medicine
Company Study of Huadong Medicine
Peru Pharmaceuticals and Healthcare Report Q2 2008
|
|
|
|
